Industry Urges Caution Over Japan HTA Plans
This article was originally published in PharmAsia News
Japan may have decided to dip an exploratory toe in the waters of health technology assessment, but the research-based pharma industry is continuing to voice early caution over potential shortcomings in methodology and expertise, and to stress the need for a holistic approach.
You may also be interested in...
Japan has reported big rises in drug costs covered by its national health insurance scheme, driven in large part by hepatitis C and cancer, adding weight to ongoing discussions of possible new cost containment measures.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.